MedPath

The efficacy of the walk-bike on quality of life and exercise capacity in patients with idiopathic pulmonary fibrosis: a pilot study.

Completed
Conditions
lung fibrosis
scarring of the long
10008401
10024967
10024450
Registration Number
NL-OMON41589
Lead Sponsor
Erasmus MC, Universitair Medisch Centrum Rotterdam
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
11
Inclusion Criteria

-IPF patients
-Diagnosis of IPF, including probable and possible diagnosis according to ATS/ERS criteria
-Written informed consent
-TLCOc >= 25% (pred) and FVC >= 50% (pred)
-6MWD >= 150 m
-Being clinically stable
-Absolute decline in TLCOc and FVC should be less than 10% in the past 6 months.

Exclusion Criteria

-Participation in a formal rehabilitation program within 4 months of start of study
-Musculoskeletal disorders
-Severe cardiac diseases (ejection fraction < 30%, daily angina, or otherwise specified by treating cardiologist)
-Unable to understand informed consent
-Other conditions that hamper the use of a walk-bike

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
<p>Change in total score in health-related quality of life questionnaire SGRQ ,<br /><br>measured at week 9 and week 18 compared to baseline.</p><br>
Secondary Outcome Measures
NameTimeMethod
<p>Change in exercise capacity measures at week 9 and week 18 compared to baseline<br /><br>(distance (m) during 6-minute-walk-test and average steps per day)<br /><br><br /><br>Change in score in health related quality of life questionnaires K-BILD abd<br /><br>GAD-7 , measured at 9 and 18 weeks compared with baseline.<br /><br>This questionnaire is self-administered.<br /><br><br /><br>Change in component scores (symptoms, activity and impact) in health-related<br /><br>quality of life measured with SGRQ at week 9 and 18 compared to baseline.</p><br>
© Copyright 2025. All Rights Reserved by MedPath